Sez6 levels are elevated in cerebrospinal fluid of patients with inflammatory pain-associated conditions.
BACE1
CSF
Chronic pain
Inflammatory pain
Seizure-related protein 6
Journal
Pain reports
ISSN: 2471-2531
Titre abrégé: Pain Rep
Pays: United States
ID NLM: 101683899
Informations de publication
Date de publication:
Historique:
received:
22
09
2018
revised:
20
12
2018
accepted:
17
01
2019
entrez:
2
5
2019
pubmed:
2
5
2019
medline:
2
5
2019
Statut:
epublish
Résumé
Seizure-related protein 6 (Sez6) contributes to chronic pain development as To determine whether this BACE1-shed form of Sez6 can be detected in the cerebrospinal fluid (CSF) and whether Sez6 levels in the CSF are altered in neuropathic pain or chronic inflammatory pain (IP). We analysed the CSF samples collected during surgery from patients with chronic neuropathic pain (n = 8) or IP (n = 33), comparing them to the CSF samples from patients with suspected subarachnoid haemorrhage that was subsequently excluded (nonsurgical group, n = 5). Western blots were used to determine the relative Sez6 levels in the CSF from the different patient and nonsurgical comparison groups. The results show that BACE1-shed Sez6 can be readily detected in the CSF by Western blot and that the levels of Sez6 are significantly higher in the IP group than in the nonsurgical comparison group. The association between elevated Sez6 levels in the CSF and IP is further evidence for persistent alterations in central nervous system activity in chronic IP conditions.
Identifiants
pubmed: 31041421
doi: 10.1097/PR9.0000000000000719
pii: PAINREPORTS-D-18-0082
pmc: PMC6455686
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e719Subventions
Organisme : NINDS NIH HHS
ID : R01 NS102722
Pays : United States
Déclaration de conflit d'intérêts
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Références
Arch Neurol. 2003 Nov;60(11):1524-34
pubmed: 14623723
Trends Neurosci. 2003 Dec;26(12):696-705
pubmed: 14624855
Eur J Neurosci. 2004 Jul;20(2):467-73
pubmed: 15233755
Brain Res Rev. 2006 Aug;51(2):240-64
pubmed: 16388853
Lancet. 2006 May 13;367(9522):1618-25
pubmed: 16698416
FEBS Lett. 2006 Jul 24;580(17):4057-64
pubmed: 16814779
Neuron. 2006 Oct 5;52(1):77-92
pubmed: 17015228
Pain. 2007 Apr;128(3):272-82
pubmed: 17276007
Neuroscience. 2007 Sep 21;148(4):925-36
pubmed: 17764852
Neuron. 2007 Nov 21;56(4):621-39
pubmed: 18031681
Br J Pharmacol. 2008 Mar;153 Suppl 1:S133-6
pubmed: 18193070
PLoS One. 2010 Jun 11;5(6):e10980
pubmed: 20552007
Pain. 2011 Mar;152(3 Suppl):S2-15
pubmed: 20961685
Neurosci Res. 2011 Feb;69(2):87-92
pubmed: 21093502
PLoS One. 2011 Feb 23;6(2):e17287
pubmed: 21383843
EMBO J. 2012 Jun 22;31(14):3157-68
pubmed: 22728825
HSS J. 2012 Feb;8(1):26-8
pubmed: 23372523
Pain Pract. 2014 Jan;14(1):79-94
pubmed: 23464879
J Psychiatr Res. 2013 Nov;47(11):1572-80
pubmed: 23962679
Osteoarthritis Cartilage. 2013 Sep;21(9):1308-15
pubmed: 23973145
Ann Rheum Dis. 2015 Apr;74(4):682-8
pubmed: 24351516
Nat Rev Drug Discov. 2014 Jul;13(7):533-48
pubmed: 24948120
Alzheimers Res Ther. 2014 Dec 24;6(9):89
pubmed: 25621019
Alzheimers Res Ther. 2015 Jul 29;7(1):53
pubmed: 26225140
Curr Rheumatol Rep. 2016 Jun;18(6):30
pubmed: 27097817
Mol Neurodegener. 2016 Oct 5;11(1):67
pubmed: 27716410
Trends Neurosci. 1993 Mar;16(3):99-104
pubmed: 7681240